Gomez Esteban, Morris Claudia R
Department of Hematology-Oncology, Children's Hospital & Research Center Oakland, Oakland, CA 94609, USA.
Biomed Res Int. 2013;2013:604140. doi: 10.1155/2013/604140. Epub 2013 Nov 10.
Asthma is a common comorbid factor in sickle cell disease (SCD). However, the incidence of asthma in SCD is much higher than expected compared to rates in the general population. Whether "asthma" in SCD is purely related to genetic and environmental factors or rather is the consequence of the underlying hemolytic and inflammatory state is a topic of recent debate. Regardless of the etiology, hypoxemia induced by bronchoconstriction and inflammation associated with asthma exacerbations will contribute to a cycle of sickling and subsequent complications of SCD. Recent studies confirm that asthma predisposes to complications of SCD such as pain crises, acute chest syndrome, and stroke and is associated with increased mortality. Early recognition and aggressive standard of care management of asthma may prevent serious pulmonary complications and reduce mortality. However, data regarding the management of asthma in SCD is very limited. Clinical trials are needed to evaluate the effectiveness of current asthma therapy in patients with SCD and coincident asthma, while mechanistic studies are needed to delineate the underlying pathophysiology.
哮喘是镰状细胞病(SCD)常见的合并症因素。然而,与普通人群相比,SCD中哮喘的发病率远高于预期。SCD中的“哮喘”是单纯与遗传和环境因素相关,还是潜在的溶血和炎症状态的结果,是近期争论的一个话题。无论病因如何,哮喘发作时支气管收缩和炎症引起的低氧血症将导致镰状化循环及SCD随后的并发症。最近的研究证实,哮喘易引发SCD的并发症,如疼痛危象、急性胸综合征和中风,并与死亡率增加相关。早期识别和积极的哮喘标准护理管理可能预防严重的肺部并发症并降低死亡率。然而,关于SCD中哮喘管理的数据非常有限。需要进行临床试验来评估当前哮喘疗法对SCD合并哮喘患者的有效性,同时需要进行机制研究来阐明潜在的病理生理学。